- Home
- DTIL vs ICCC Comparison
DTIL vs ICCC Comparison
Compare DTIL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- ICCC
- Stock Information
- Founded
- DTIL 2006
- ICCC 1982
- Country
- DTIL United States
- ICCC United States
- Employees
- DTIL N/A
- ICCC N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- ICCC Health Care
- Exchange
- DTIL Nasdaq
- ICCC Nasdaq
- Market Cap
- DTIL 43.3M
- ICCC 39.2M
- IPO Year
- DTIL 2019
- ICCC 1987
- Fundamental
- Price
- DTIL $5.93
- ICCC $5.02
- Analyst Decision
- DTIL Strong Buy
- ICCC
- Analyst Count
- DTIL 3
- ICCC 0
- Target Price
- DTIL $37.67
- ICCC N/A
- AVG Volume (30 Days)
- DTIL 123.5K
- ICCC 4.0K
- Earning Date
- DTIL 03-26-2025
- ICCC 02-25-2025
- Dividend Yield
- DTIL N/A
- ICCC N/A
- EPS Growth
- DTIL N/A
- ICCC N/A
- EPS
- DTIL 1.45
- ICCC N/A
- Revenue
- DTIL $75,096,000.00
- ICCC $23,838,001.00
- Revenue This Year
- DTIL $51.35
- ICCC N/A
- Revenue Next Year
- DTIL N/A
- ICCC N/A
- P/E Ratio
- DTIL $4.07
- ICCC N/A
- Revenue Growth
- DTIL 43.62
- ICCC 46.37
- 52 Week Low
- DTIL $3.61
- ICCC $3.34
- 52 Week High
- DTIL $19.43
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- DTIL 63.88
- ICCC 47.31
- Support Level
- DTIL $4.60
- ICCC $4.84
- Resistance Level
- DTIL $5.23
- ICCC $5.25
- Average True Range (ATR)
- DTIL 0.36
- ICCC 0.27
- MACD
- DTIL 0.13
- ICCC -0.04
- Stochastic Oscillator
- DTIL 88.67
- ICCC 27.27
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.